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Prostate cancer (PC) stratification needs new prognostic tools to reduce overtreatment.
Phosphatase of regenerating liver (PRL-3) is a phosphatase found at high levels in several
cancer types, where its expression is associated with survival. A recent PC cell line study
has shown it to be involved in PC growth and migration.
Methods
We used a monoclonal antibody to evaluate the expression of PRL-3 in PC tissue of patients
in an unselected cohort of 535 prostatectomy patients. We analyzed associations between
PRL-3 expression and biochemical failure-free survival (BFFS), clinical failure-free survival
(CFFS) and PC death-free survival (PCDFS).
Results
Cytoplasmic PRL-3 staining in tumor cells was significantly correlated to expression of
molecules in the VEGFR-axis, but not to the clinicopathological variables. High PRL-3
was not significantly associated with survival in the univariate analysis for BFFS (p =
0.131), but significantly associated with CFFS (p = 0.044) and PCDFS (p = 0.041). In multi-
variate analysis for the various end points, PRL-3 came out as an independent and signifi-
cant indicator of poor survival for BFFS (HR = 1.53, CI95% 1.10–2.13, p = 0.012), CFFS
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(HR = 2.41, CI95% 1.17–4.98, p = 0.017) and PCDFS (HR = 3.99, CI95% 1.21–13.1,
p = 0.023).
Conclusions
PRL-3 is independently associated with all PC endpoints in this study. Since high PRL-3
expression also correlates with poor prognosis in other cancers and functional studies in PC
support these findings, PRL-3 emerges as a potential treatment target in PC.
Introduction
Prostate cancer (PC) is the fourth most common cancer overall and the second most common
in men worldwide [1]. Presently, the identification of clinically relevant PC is challenging
since overdiagnosis and overtreatment coexist, while many die of aggressive PC [2]. There are
ongoing efforts to improve the identification of aggressive PC, but these efforts are hampered
by the lack of useful tools. Although recent efforts, like the composite pre-biopsy STHLM3
model, are entering the field[3], the morphology grade scored by pathologists is still today the
strongest predictor of aggressive disease[4]. Besides, there is currently no widely used prognos-
tic molecular tissue markers in PC. Hence, improved prognostic and more so predictive
molecular markers are urgently needed in this field.
Phosphatase of regenerating liver (PRL)-3 is a dual specificity phosphatase with ability to
dephosphorylate tyrosine, serine and threonine residues. In 2001, Vogelstein’s group sug-
gested that the PRL-3 gene (gene name: PTP4A3) is important for colorectal cancer metasta-
sis as they found high levels of PTP4A3 expression in metastases from colorectal cancer
compared to non-metastatic tumors and normal colorectal epithelium[5]. Studies have
found PRL-3 to be associated with epithelial-mesenchymal transition (EMT) and cancer pro-
gression[6]. Other studies have shown PRL-3 to be associated with metastatic potential and
poor prognosis in a large number of cancers[7–16], as well as being upregulated in myeloma
cells[17]. Due to these studies, PRL-3 has been proposed a promising biomarker for assessing
tumor aggressiveness and metastatic potential[18]. In addition, targeting of PRL-3 has been
proposed and several studies have recently reported endogenous suppressing proteins[19]
and a new humanized antibody against PRL3 (PRL3-zumab) has been tested in orthotopic
gastric tumors[20].
In PC, PRL-3 has previously been identified as a mediator of PC progression and aggres-
siveness in an integrated assessment of aggressiveness through gene copy number and gene
expression analyses[21]. As PRL-3 is a potential cancer biomarker and biomarkers in PC are
in high demand, Exploring the expression and biological role of PRL-3 in PC cells, Vandsemb
et al [22] found PRL-3 mRNA to be highly expressed in PC tissue compared to benign prostate
tissue, and the PRL-3 protein was expressed in both primary PCs and regional lymphatic
metastasis. Further in vitro studies found inhibition to induce growth arrest and decreased
migration of PC cancer cells. They also evaluated and found PRL-3 expression in 4/4 cases by
immunohistochemistry.
To further explore PRL-3’s role in PC, we aimed to elucidate the expression profile and
prognostic impact of PRL-3 in a large cohort of PC patients. Herein, we present the results
using a validated PRL-3 antibody on tissue microarrays (TMAs) from a large, well described
retrospective cohort with an extensive follow-up[23].
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Material and methods
Patients, tissue micro arrays and endpoints
Patients were included after retrospective identification of 671 patients from the archives of
the departments of pathology in two health regions in Norway, undergoing radical prostatec-
tomy (RP) for adenocarcinoma of the prostate between 01.01.1995 to 31.12.2005. One-hun-
dred and thirty-one (131) patients were excluded, due to non-available tissue blocks for re-
evaluation (St. Olav n = 112, NLSH n = 3, UNN n = 15) [23]. A total of 535 eligible patients
with available tissues and complete follow-up data were included in this retrospective cohort
study. Two-hundred and twenty-eight (228) patients were from St. Olav Hospital/Trondheim
University Hospital (St. Olav) in the Central Norway region, and 59 from Nordlandssykehuset
Bodo (NLSH) and 248 from the University Hospital of North Norway (UNN), both in the
Northern Norway region. In total, 435 patients were submitted to open retropubic resection
and 100 patients had perineal resection.
From the cohort we constructed 12 tissue micro array (TMA) blocks. A tissue-arraying
instrument (Beecher Instruments, Silver Springs, MD, USA) was used to harvest cores from
formalin-fixed paraffin-embedded (FFPE) tissue blocks from included patients. Two cores
were sampled from the most dedifferentiated neoplastic cell compartment, hereafter desig-
nated tumor. Furthermore, two cores were sampled from reactive tumor stroma, hereafter des-
ignated stroma. The cores were carefully inserted into paraffin blocks. Then, 4 μm sections
were cut by a Micron microtome (HM355S) and affixed to glass slides prior to immunostain-
ing and scoring.
Biochemical failure (BF) was defined as a PSA 0.4 ng/ml and BF-free survival (BFFS) was
calculated as time from surgery to last follow up (FU) date or date with PSA 0.4 ng/ml. Clin-
ical failure (CF) was defined as symptomatic, locally advanced progression or radiologically
verified metastasis to bone, visceral organs or lymph nodes. Clinical failure-free survival
(CFFS) was calculated as time from surgery to last fFU date without CF or to date of CF. Last
follow-up update was December 2015, and calculated median follow-up of survivors was 150
months.
For more extensive information regarding patients, exclusion, definitions of variables and
endpoints, see our previous report[23].
Immunohistochemistry
TMA paraffin block sections slides were dried overnight at 37˚C. PRL-3 immunohistochemi-
cal staining of the cut sections was performed using the Ventana Discovery ULTRA autostai-
ner (Tucson, Arizona, USA). After paraffin embedded tissues were dewaxed, antigen retrieval
was applied using Ventana ULTRA Cell Conditioning-1 (CC1) for 32 minutes at 95˚C. Endog-
enous peroxidase was blocked by discovery inhibitor CM (#760–4306, Ventana) for 12 min-
utes. Sections were incubated with non-commercial mouse monoclonal antibody[24, 25]
(kind gift from professor Qi Zeng, Agency for Science, Technology and Research (ASTAR),
Singapore) with 1/50 dilution for 32 minutes at 36˚C. As secondary antibody, OmniMap anti-
mouse HRP (#760–4310, Ventana) was loaded for 20 minutes, followed by 8 minutes of HRP
amplification. The detection chromogen was ChromoMap DAB (#760–159; Ventana). Coun-
terstaining was performed using the hematoxylin II (#790–2208, Ventana) counterstain for 32
minutes and then with a bluing reagent for 8 minutes. Staining was performed in one single
experiment and a human multiple organ (normal and malignant) tissue array was included for
specificity control of antibody. Normal tonsil and liver adenocarcinoma were used as negative
and positive tissue controls, respectively.
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Scoring of immunohistochemistry and cut-offs
PRL-3 expression was scored semiquantitatively. We initially explored the expression with our
dedicated uropathologist (E.R.), and agreed on scoring definitions and scales. Then, two scor-
ers (E.R, M.R) performed all scoring and reported the scores independently of each other. We
sought to assess expression in applicable compartments (tumor, non-malignant epithelium
and stroma) and different cell compartments (cytoplasmic, nuclear or membranous). Scorable
PRL-3 expression was only possible where positivity was present in more than a minor subset.
We ended up with the following scoring scale based on observed expression: A. Tumor cyto-
plasmic cell intensity on a four-tier scale (0 = negative, 1 = weak, 2 = intermediate, 3 = strong),
and B. Tumor nuclear density on a four tier scale (0 = 0%, 1 = 0–5%, 2 = 5–50% and 3>50%
of nuclear tumor cells stained). A cut-off of 1.5 was defined for all analyses.
Statistical analyses
We used the SPSS software version 23 (IBM SPSS Inc., Chicago, IL, USA) for statistical analy-
ses. For the Inter-observer reliability of scoring, we used the two-way random effect model
with absolute agreement. Correlations between PRL-3, previous explored markers and clini-
copathological variables were assessed by the Spearman Correlation test. The log-rank test
was used for testing statistical significance of difference between survival curves. Survival
curves were drawn by use of the Kaplan-Meier method. The curves were terminated when
less than 10% of patients were still at risk (192 months). For the multivariate analyses, we
used a backward Cox regression model with a probability at 0.10 for entry and 0.05 for
removal. Clinicopathological variables from the univariate analyses with a p < 0.10 were
entered. The significance level defined for all analyses was p < 0.05.
Ethics
This study was approved by the regional ethics committee, REK Nord, project application
2009/1393 (including a mandatory re-application which was formally approved 22.01.2016.
The committee waived the need for patient consent for this retrospective study. The reporting




There was specific and variable cytoplasmic staining, which when present, was frequently
accompanied by a granular accentuation. There was also strong nuclear staining in a subset of
tumor cells. In stroma, a small subset of fibroblasts had some nuclear staining. Most lympho-
cytes, when present, also had a strong nuclear staining. Expression of PRL-3 was also present
in benign epithelium in this study, although its extent was not systematically evaluated. Inter-
observer scoring agreement was; Intraclass correlation coefficient (ICC) = 0.89 for tumor cyto-
plasm intensity and ICC = 0.93 for tumor cell nuclear staining. The fibroblast staining was
hard to score due to very low intensity, resulting in an ICC of 0.44. Photomicrographs of low
versus high expression examples of cytoplasmic tumor cell expression of PRL-3 are presented
in Fig 1. For examples of IHC staining in whole tissue sections, see S1 Fig.
Of the total cohort, 397 patients had cores with morphologically verified malignant cells
available for scoring. In tumor cell cytoplasm, the mean expression score was 1,25, (range 0–3)
and the most prevalent score was 1 (n = 112). For tumor nuclear staining, the mean expression
score was 0.48 with 0 as the most prevalent score (n = 225). For fibroblasts, only 56 had some
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cytoplasmic staining detected by at least one of the observers. The ICC for fibroblast scoring
was weak and considered unreliable for further analyses.
Correlations
We observed a positive and significant correlation between cytoplasmic and nuclear PRL-3
staining (r = 0.42, p< 0.001). There was no significant correlation with r> 0.1 between
clinicopathological variables and cytoplasmic or nuclear PRL-3 staining. However, we found
cytoplasmic PRL-3 staining to correlate to the following molecular markers previously evalu-
ated in our cohort; tumoral VEGF-A (r = -0.21, p< 0.001), tumoral VEGFR-2 (r = 0.22,
p< 0.001) and tumoral VEGFR-3 (r = 0.31, p< 0.001). The markers it did not correlate to
were monocarboxylate trasporter 1 and 4, CD3, CD4, CD8, CD 20, CD56, CD68, CD138,
Fig 1. Illustrative examples of immunohistochemical staining for PRL3. A) a whole core at 200 magnification exhibiting low expression, B) An
image of the same core as A at 400X magnification, C) a whole core at 200x showing high expression of PRL-3, D) an image taken 400x in the same
core as C. This image also serves as an example of high expression in fibroblast nuclei.
https://doi.org/10.1371/journal.pone.0189000.g001
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PD1, progesterone receptor, estrogen receptor and aromatase. For nuclear PRL-3 staining, we
found no significant correlations with r> 0.1.
Univariate analyses
For nuclear PRL-3 expression there was no significant association to BFFS or CFFS. For cyto-
plasmic expression of PRL-3 we found associations between high expression of PRL-3 and
poor BFFS (p = 0.131, Table 1 and Fig 2A), poor CFFS (p = 0.044, Table 1 and Fig 2B) and
poor PCDFS (p = 0.041, Table 1 and Fig 2C). When exploring different cut-offs, we found a
trend for worse survival for all cut-offs with variable p-values. The same tendency or signifi-
cance was observed within each relevant clinicopathological subgroup (PSA, age, Gleason,
pTstage, Tumor size, perineural infiltration and vascular infiltration).
Multivariate analyses
For the multivariate analyses we entered all clinicopathological variables with a p<0.10 from
the univariate analyses in addition to the prognostically significant PRL-3 variable, cytoplasmic
tumor cell expression of PRL-3. These variables are in bold in Table 1 and were entered in the
three models according to different survival end points; BFFS, CFFS and PCDFS. However, for
the last model with PCDFS there were only 18 events, which according to stringent statistical
procedures, do not allow more than three variables to be entered. In all models (Table 2) cyto-
plasmatic PRL-3 expression in tumor cells was an independent prognosticator for poor event-
free survival (BFFS, HR = 1.53, CI95% 1.10–2.13, p = 0.012; CFFS, HR = 2.41, CI95% 1.17–
4.98, p = 0.017; PCDFS, HR = 3.99, CI95% 1.21–13.1, p = 0.023).
Discussion
In our large retrospective PC cohort, we found high cytoplasmic tumor cell expression of PRL-
3 to be independently associated to all investigated endpoints; BF, CF and pPCdeath.
This is the first study to evaluate the prognostic impact of PRL-3 in PC. It follows a func-
tional study on the role of PRL-3 in PC [22] and thereby further verifies its significance in PC.
In addition to a functional study-based hypothesis, strengths of this study are the large well-
defined cohort with long follow-up, a validated antibody using a well-adopted method (IHC),
and consistent results across several endpoints. Weaknesses are the retrospective design and
the lack of a training set to determine cut-offs for validation.
The many previous studies with different methods for PRL-3 detection have implicated its
role in cancer, mostly demonstrating associations between high expression and poor progno-
sis. Associations between high protein expression and poor prognosis have been found in a
variety of cancers; breast cancer[10, 26–29], colorectal cancer[7, 9, 30], gastric cancer[13, 31–
34], hepatocellular carcinoma[35], cholangiocarcinoma[36], nasopharyngeal carcinoma[37],
ovarian cancer[38] and adenoid cystic carcinoma [16], although there have been negative stud-
ies too [39].
Studies points to an important role of PRL-3 in cancer progression and metastasis. Initially
PRL-3 was proposed as a phosphatase for metastasis[40], but multiple pathways and mecha-
nisms have been implied to exert the effects of high PRL-3 expression. PRL-3 is a member of
the PRL protein tyrosine phosphatase family and is the most studied of these so far [6, 41]. All
(PRL-1, PRL-2 and PRL-3) promote proliferation, migration, invasion and metastasis[6]. PRL-
3 has specifically been implicated in activation of acknowledged cancer progression pathways
like phosphatidylinositol-3 kinase[42], regulating mTOR activation[43], Src tyrosine protein
kinase[44, 45], epidermal growth factor receptor (EGFR)[46], and ERK[15]. Regulation of
PRL-3 is found at several levels (transcriptional, translational and post translational) and is
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Table 1. Patient characteristics and clinicopathological variables, and their prognostic value for biochemical failure, clinical failure and prostate
cancer death in 535 prostate cancer patients (univariate analyses; log rank test).
Characteristic Patients (n) Patients(%) BF (200 events) CF (56 events) PCD(18 events)
5-year EFS (%) p 10-year EFS (%) p 10-year EFS (%) p
Age 0.237 0.038 0.404
 65 years 357 67 77 94 98
> 65 years 178 33 70 91 98
pT-stage <0.001 <0.001 <0.001
pT2 374 70 83 97 99
pT3a 114 21 61 87 98
pT3b 47 9 43 74 91
Preop PSA <0.001 0.029 0.003
PSA<10 308 57 81 95 99
PSA>10 221 42 68 89 97
Missing 6 1 - -
Gleason <0.001 <0.001 <0.001
3+3 183 34 83 98 99
3+4 219 41 77 94 99
4+3 81 15 70 90 96
4+4 17 4 58 86 94
9 35 6 37 65 90
Tumor Size <0.001 0.002 0.085
0–20 mm 250 47 83 96 99
>20 mm 285 53 68 90 97
PNI <0.001 <0.001 <0.001
No 401 75 80 96 99
Yes 134 25 60 83 95
PSM 0.049 0.198 0.843
No 249 47 81 96 98
Yes 286 53 69 90 98
Non-apical PSM <0.001 <0.001 0.022
No 381 71 82 96 99
Yes 154 29 57 85 96
Apical PSM 0.063 0.427 0.128
No 325 61 74 92 98
Yes 210 39 77 93 99
LVI <0.001 <0.001 <0.001
No 492 92 77 95 99
Yes 43 8 47 69 90
PRL-3 expression in tumor cytoplasm 0.131 0.044 0.041
Low expression 236 44 76 95 99
High expression 161 30 72 92 96
Missing 138 26 - - -
PRL-3 expression in tumor nucleus 0.123 0.819 0.491
Low expression 225 42 71 94 98
High expression 172 32 79 94 98
Missing 138 26 - -
Abbreviations: BF = biochemical failure; CF = Clinical failure; LVI = lymphovascular infiltration; PCD = Prostate cancer death; PNI = Perineural infiltration;
Preop = preoperative; PSA = Prostate specific antigen; PSM = Positive surgical margin
“Missing” corresponds to missing evaluable tumor tissue for this patient in our TMA cores.
https://doi.org/10.1371/journal.pone.0189000.t001
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mediated by several factors such as p53, TGFβ, STAT3, VEGF, Snail, PCBP1, Src etc [6, 47].
Hence, its function is complex and probably finely tuned within specific compartments.
In PC, its function has been studied in a few studies. A thorough exploration by members
of our group [22] revealed several novel PC-specific findings. PRL-3 was found to be expressed
at higher levels in PC tissue than in normal prostate tissue, and was ranked among the genes
most differentially expressed between cancerous and benign prostate tissue. In PC cell lines,
PRL-3 was present and gene amplication was found to be a possible explanation. Further, inhi-
bition of PRL-3 hampered the PC cell lines’ ability to proliferate, reduced their survival and
decreased cell migration. In a small exploration of primary PC tissue and corresponding
affected lymph nodes from four patients, they found no difference in expression between the
metastases and primary tumor. Taken together, PRL-3 expression is probably an early event in
PC tumor progression, and inhibition of PRL-3 causes reduction of pathogenic properties like
migration and growth while increasing apoptosis.
This study have implications for future biomarker research in PC. In contrast to many
other biomarker studies in PC, PRL-3 was significant for all clinically relevant endpoints, and
it should have priority for further validation. In particular since previous biomarker studies in
PC only have significant results for BF. In addition, PRL-3 has consistently been found associ-
ated with poor prognosis also in several other malignancies. Besides, PRL-3 may have potential
as a therapeutic target. The findings from functional studies in various cancers including PC
indicates PRL-3 to be an attractive target.
There are currently no ongoing clinical studies targeting PRL-3. However, over the last
decade multiple novel PRL-3 inhibitors have been developed[48–53] and several natural
occurring compounds are found to have PRL-3-inhibitory properties[54–58], both with clear
in vitro effects on various types of cancer cells. In vitro studies have also investigated effects of
PRL-3 inhibition on PC cells. In an explorative study on the effect of curcumin, this agent
decreased PRL-3 mRNA levels in PC3 cells[59]. A marine macrolide (halichondramide) had
anti-metastatic activity in highly metastatic PC3 human PC cells due to PRL-3 inhibition. The
first chimeric antibody targeting PRL-3 was engineered in 2012[60]. Recently, a humanized
antibody against PRL-3 (PRL3-zumab) was generated and proved effective towards human
gastric cancer cells[20]. Interestingly, effects were associated with PRL-3 positive cells, suggest-
ing expression of PRL-3 to be a possible predictive biomarker for future PRL-3 directed ther-
apy. Our findings of RPL-3 to be primarily expressed in neoplastic and not stromal PC cells
support the idea of specific tumor effects by inhibition. Though, this remains to be tested in
preclinical studies prior to early phase clinical studies.
Fig 2. PRL-3 survival curves. Kaplan meier curves stratified by high and low expression of PRL-3 for A) biochemical failure-free survival, B) clinical
failure-free survival and C) prostate cancer death free survival. The p-value is the univariate log rank p-value.
https://doi.org/10.1371/journal.pone.0189000.g002
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Conclusions
This is the first study to address the prognostic impact of PRL-3 in PC. We have verified our
hypothesis that high tumor cell expression of PRL-3 is a strong independent predictor for clin-
ically relevant PC endpoints such as BF, CF and PC death. These results strongly suggest PRL-
3 as a prognostic biomarker in PC, although further validation is needed. Based on the results
from this study, PRL-3 is suggested as a potential therapeutic target due to expression mostly
in cancer cells.
Table 2. Multivariate analyses of factors with a p < 0.10 in univariate analyses (see Table 1) for all patients (Cox regression, backward conditional).
Significant p-values in bold (threshold p 0.05).
Characteristic BF (200 events) CF (56 events) PCD (18 events)*
HR CI95% p HR CI95% p HR CI95% p
Age NE NS NE
pT-stage <0.001 NS NE
pT2 1
pT3a 1.56 1.04–2.33 0.031
pT3b 3.14 1.45–3.97 <0.001
Tumor Size NS NS NE
0–20 mm
>20 mm
Preop PSA NS 0.018
PSA<10 1 1
PSA>10 1.49 1.07–2.11 0.02 4.74 1.30–17.3
ISUP grade (Gleason) NS 0.003 NS
1 (3+3) 1
2 (3+4) 2.74 0.75–10.1 0.127
3 (4+3) 5.39 1.40–20.7 0.014
4 (4+4) 10.7 2.11–54.4 0.004
5 (9) 10.3 2.59–41.3 0.001
PNI 0.003 NS 0.002
No 1 1
Yes 1.74 1.21–2.49 5.95 1.94–18.3
LVI NS 0.007 NE
No 1
Yes 3.35 1.38–8.13
Non-apical PSM 0.019 NS NE
No 1
Yes 1.53 1.07–2.19
PRL-3 expression in tumor cytoplasm 0.012 0.017 0.023
Low expression 1 1 1
High expression 1.53 1.10–2.13 2.41 1.17–4.98 3.99 1.21–13.1
Abbreviations; BF = biochemical failure; CF = Clinical failure; LVI = lymphovascular infiltration; NE = not entered, due to non-significance in the univariate
analyses; NS = not significant, the characteristic is removed by the backward conditional analysis due to insignificance; PCD = Prostate cancer death;
PNI = Perineural infiltration; Preop = preoperative; PRL-3 = Phosphatase related to the liver- 3; PSA = Prostate specific antigen; PSM = Positive surgical
margin
*Due to the low number of events in the PCD model only three variables could be entered in the model. We therefore did a careful analysis to select only the
two variables other than PRL-3 that where truly independent by performing initial multiple enter analyses.
https://doi.org/10.1371/journal.pone.0189000.t002
PRL-3 is associated to poor prognosis in PC
PLOS ONE | https://doi.org/10.1371/journal.pone.0189000 November 30, 2017 9 / 13
Supporting information
S1 Fig. Immunohistochemical expression of PRL-3 in whole section. PRL-3 staining in a
whole section illustrating nuclear and cytoplasmic expression in both malignant and benign
epithelium.
(JPG)
S1 File. Database file. This is the SPSS database file with scoring and survival data for the
patients within this cohort.
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